Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Reduced efficacy of an anti-toxin vaccine from senescence-driven attenuation of toxin virulence
Xin Du, Ching Wen Tseng, Elisabet Bjånes, Hunter Gage, Jaclyn Swan, Chih-Ming Tsai, Irshad A. Hajam, Cesia Gonzalez, Brian Lin, Victor Nizet, George Y. Liu
Xin Du, Ching Wen Tseng, Elisabet Bjånes, Hunter Gage, Jaclyn Swan, Chih-Ming Tsai, Irshad A. Hajam, Cesia Gonzalez, Brian Lin, Victor Nizet, George Y. Liu
View: Text | PDF
Research Article Infectious disease Microbiology

Reduced efficacy of an anti-toxin vaccine from senescence-driven attenuation of toxin virulence

  • Text
  • PDF
Abstract

It remains unclear why vaccines targeting prominent microbial virulence factors often fail in clinical trials. Because microbial virulence depends on interaction with the host immune system, we investigated how changes in host immune function alter vaccine efficacy. Using a vaccine against Staphylococcus aureus α-toxin (Hla), which targets host metalloprotease ADAM10 on myeloid cells, we show that Hla virulence is reduced in aged mice due to diminished ADAM10 activity and impaired myeloid cell function. Depletion of myeloid cells with cyclophosphamide in young mice similarly reduced toxin virulence. Immunization against Hla conferred strong protection against S. aureus infection in young but not aged mice. These findings indicate that pathogenic functions of microbial factors characterized in immunocompetent young animals may not predict virulence or vaccine efficacy in immunocompromised hosts. These findings underscore the need to account for host immune status in the development and evaluation of vaccines targeting microbial virulence factors.

Authors

Xin Du, Ching Wen Tseng, Elisabet Bjånes, Hunter Gage, Jaclyn Swan, Chih-Ming Tsai, Irshad A. Hajam, Cesia Gonzalez, Brian Lin, Victor Nizet, George Y. Liu

×

Figure 4

Bone marrow–derived immunocytes contribute to reduced Hla activity in aged mice.

Options: View larger image (or click on image) Download as PowerPoint
Bone marrow–derived immunocytes contribute to reduced Hla activity in ag...
(A) Schematic: Bone marrow cells from young or aged mice were injected into 1- to 3-day-old NSG mice. At 16–20 weeks of age, the mice were analyzed for reconstitution and then challenged with Hla or S. aureus. (B and C) Percentage of splenic CD45+ cells and blood CD11b+ cells (n = 6–12 for CD45 and n = 3–4 for CD11b analysis). (D and E) Enzymatic activities of ADAM10 in neutrophil and skin lysates (n = 3–4). (F) Skin lesion sizes 3 days after Hla challenge (n = 5–9). (G) Skin lesions sizes 3 days after infection with WT or Δhla S. aureus (n = 5–6). Each data point represents an individual mouse. Line in B, C, F, and G represents the mean. The data in D and E are presented as mean ± SEM of biological replicates. *P < 0.05; **P < 0.01; ***P < 0.001 by 2-tailed non-parametric Mann-Whitney U test (B, C, and F) or Kruskal-Wallis non-parametric 1-way ANOVA test (D, E, and G). NS, not significant; NSG, NOD/SCID/IL2rγnull mouse; Y.BM, NSG recipients of bone marrow from young C57BL/6 mice; A.BM, NSG recipients of bone marrow from aged C57BL/6 mice; GI254023X, ADAM10 inhibitor in DMSO; control, DMSO. The schematic in A was created in BioRender (https://BioRender.com/h2vi3i1).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts